Sponsors of the Event are the Azrieli College of Engineering, AtoBe – Azrieli College of Engineering Startup Accelerator and the Jerusalem Chamber of Commerce.<a> </a>
Join JBNF-Biomed celebrations for the New Year
Oct 31 17:30 * Azrieli College of Engineering
• Join us for JBNF-Biomed’s launch of “JLM-BioCity”, a new private groundbreaking initiative to coordinate Jerusalem’s biomed entrepreneurs, professionals and academics into a world-leading biomed cluster.
• A discussion on how Jerusalem can become into a leading global Life Science Industry Hub with a panel of leading bio entrepreneurs and visionaries.
• Hear how Denmark and Sweden made the Medicon valley into Europe’s leading Life Science Industry Hub.
The event will coincide with the launch of the new JLM-BioCity.org site, with new services, blogs, LinkedIn group (covering JLM-BioCity News), Facebook page and job board.
Moderators: Tamar Tannenbaum & Yaron Suissa – JLM-BioCity.org
Rosa Azhari, President, Azrieli College of Engineering
Debbie Shalev, Head, Pharmaceutical Engineering, Azrieli College of Engineering
Shai Melcer, Executive Director, Bio-Jerusalem
1. Launching of JLM-BioCity – Yaron Suissa, CSO & COO, Molecular Detection Israel Ltd. & CEO, JLM-BioCity.org
2. Memorial for Dr Nahum Kowalsky z”l – Avigail Frij, VP, Logistics, JLM-BioCity
3. “The Ministry of Health’s New Digital Health Strategy”
Nir Yanovsky, Digital Health Implementation Manager, Ministry of Health
4. The Medicon Valley success story – a Model for Jerusalem Bio Community?
– Louise Vibjerg Thomsen, Commercial Counsellor/ Head, Team Trade & Innovation, Royal Danish Embassy
5. “Making Jerusalem into a Global Biotech Leader.”
Panel Discussion with:
• Tamar Tennenbaum, CEO, Tencure & CTO Aravot Biotech & VP, Strategic Affairs, JLM-BioCity, Moderator
• Avi Domb, Professor, Biomaterials and Medicinal Chemistry, Faculty of Medicine, Hebrew University of Jerusalem
• Jeff Dykan, Partner, SCP Vita Life
• Noam Shamir, General Manager, Jerusalem Operations, <a>Teva</a>
• Nurit Tweezer-Zaks, Prospective & Strategic Initiatives, Scouting & Partnering, Sanofi
• Marta Weinstock-Rosin, Dr Lein & Dr Mina Deutsch Prof Emerita of Psychophamacology, Hebrew University of Jerusalem
6. Questions & Answers
The panel will address the strengths that need to be capitalized, the hurdles to overcome, and the importance of working together to make this dream into a reality.
The event will also commemorate the recent passing of Dr Nahum Kowalsky z”l, a dear friend and a health care visionary who pioneered new personalized medical data technologies for enhancing patient care. Esteemed and beloved member of JBNF-Biomed and creator of thought-provoking publications, Nahum’s vision of benefiting humankind by advancing medical technology and techniques will remain with us in all our endeavors.
JLM-BioCity (JBNF-BioMed) is delighted to announce that the event is sponsored by Azrieli College of Engineering, AtoBe – Azrieli College of Engineering Startup Accelerator and the Jerusalem Chamber of Commerce.
Please send your name in Hebrew and car licence plate to firstname.lastname@example.org to get parking permit for your care at the event. Write in the subject of your email – Oct 31 JLM-BioCity -car parking permit.
JLM-BioCity is a private initiative of bio entrepreneurs, professionals and businesspeople in making Jerusalem a global life science innovation leader and Bio-Capital of Israel. The sponsors of JLM-BioCity are:
About the Medicon Valley
The Danish-Swedish Øresund region or Medicon Valley is Europe’s leading life science clusters. With over 350 life science companies ( +200 pharma, 170 medtech), employing 40,000 and some 80 CRO/CMOs situated in 7 science parks and 3 life science incubators, the Medicon Valley exports over $ 10 billion in life science products. The triple combination of government agencies, research infrastructure and business networks is behind the success of the Medicon Valley which was started in 1997 as an initiative of the universities in Lund and Copenhagen, strongly supported by the major local pharmaceutical companies; Novo Nordisk, Lundbeck and Astra-Zeneca. The Danish and Swedish authorities run the government The Medicon Valley which works with the private initiative, the Medicon Valley Alliance.
ABOUT THE SPEAKERS
Yaron Suissa, CSO & COO, Molecular Detection Israel Ltd & CEO, JLM-BioCity
Dr. Suissa’s holds his degrees from the Hebrew University and led the pre-clinical research testing for a new treatment for Pancreatic Neuro-Endocrine Tumors. He served as the head of R&D at TenCure, Manager of business development and operations at NextGen-BioMed and is the CSO and COO at Molecular Detection Israel LTD. He is the CEO of JLM-BioCity.
Louise Vibjerg Thomsen, Commercial Counsellor/ Head, Team Trade & Innovation, Royal Danish Embassy
Louise Vibjerg Thomsen is Commercial Counsellor, Head of Trade & Innovation at the Danish Embassy in Tel Aviv since 2014. As such, Louise Thomsen is responsible for assisting Danish companies and research institutions in identifying strategic collaboration opportunities in Israel within trade, innovation and research. The main focus areas are Life Science, Cleantech and Entrepreneurship.
Louise holds an MA in Cross Cultural Business Communication with special emphasis on international negotiation from the University of Aarhus in Denmark and has been working with international business and innovation in Israel for the past 6 years. Prior to this, Louise Thomsen worked for six years as project manager of Danida-funded (Danish Foreign Aid) projects in Israel.
Tamar Tennenbaum, CEO, Tencure & CTO, Aravot Biotech & Vice President, Strategic Affairs, JLM-BioCity Steering Committee
Tamar Tennenbaum, MD, Ph.D. holds her degrees from the Hebrew University and has over 50 scientific publications and 40 granted patents. She is an established BioMed entrepreneur specializing in discovery and development of innovative pharmaceuticals. She was the founder and CEO of HealOr and TenCure and is currently the CTO of Arava BioTech. She is also Vice President, Strategic Affairs of JLM-BioCity.
Avi Domb, Professor, Biomaterials and Medicinal Chemistry, Faculty of Medicine, Hebrew University of Jerusalem
Abraham J. Domb is a Professor for Medicinal Chemistry and Biopolymers at the School of Pharmacy- Faculty of Medicine of the Hebrew University. He earned Bachelors degrees in Chemistry, Pharmaceutics & Law studies and PhD degree in Chemistry from The Hebrew University. He did his postdoctoral training at MIT and Harvard Univ. Cambridge USA and was R&D manager at Nova Pharm. Co. Baltimore US during 1988-1991. Since 1991 he is a faculty member at the Hebrew university, full Prof. since 1999. During 2007-2012 he headed the Division of Forensic Science at the Israel Police. During 2014 -2016 he served as President of the Jerusalem College of Engineering (JCE). The Products he developed are: GliadelTM; Superfloc HX-100TM; SkedaddleTM; TaddaTM; MAZE Water MakerTM; DeximmuneTM; Canker CoverTM;OramoistTM; InSpaceTM; ProSpaceTM; I-ABNTM. His current areas of interest include: biopolymers, functional polymers, oral, topical and injectable drug delivery systems, water treatment and forensic sciences.
Jeff Dykan, partner, SCP Vita Life
Jeff Dykan has been a Managing Partner with Vitalife since 2002 where he has a lead role in managing its investments, including arranging financing and M&A.
Prior to Vita Life, he was recruited by Sequoia Capital as Chairman & CEO, BitBand, an IP broadband start up, and successfully turned that company around. Before BitBand, he held several senior financial positions, including CFO at VocalTec Communications, Director of Regional Finance for Applied Materials in Israel and VP Finance at Opal. He began his career in 1981 with Andersen Consulting in New York.
Currently, Chair of ReWalk Robotics and Trig Medical, on the board of directors of NovoGI, Regentis Biomaterials, Deep Breeze and Beta-O2 Technologies, and previously a board member of Colbar Lifescience (acquired by J&J) and Can-Fite BioPharma (TASE: CFBI).
He has a B.S. in accounting and management and an MBA in computer applications, both from New York University.
Noam Shamir, General Manager, Jerusalem Operations, <a>Teva Pharmaceuticals</a>
Nurit Tweezer-Zaks, Prospective & Strategic Initiatives, Scouting & Partnering, Sanofi
Marta Weinstock-Rosin, Dr Lein & Dr Mina Deutsch Prof Emerita of Psychophamacology, Hebrew University of Jerusalem
Marta Weinstock-Rosin, Ph.D. serves as Scientific Founder and Director of Avraham Pharmaceuticals Ltd. She is a co-inventor of Ladostigil, and Professor Emeritus at the Hebrew University, Jerusalem, Israel. She was Chairperson of the Department of Pharmacology from 1983 to 986, and President of the Israel Society for Neuroscience from 2003 to 2005. She has served on the Editorial board of Journals of Pharmacology and of Neuroscience, numerous University Committees and the Board of the Israel Society for Psychobiology. She was awarded the Kaye prize for the invention of Exelon in 2000 and was the first person working in a university to be awarded a prize by the Institute of Ageing, USA for inventing Rivastigmine (Exelon®, Novartis Pharmaceuticals), a drug for the treatment of Alzheimer’s Disease. She has co-authored more than 200 research papers, invited reviews and book chapters, and supervised more than 50 postgraduate students for their M.D., M.Sc. and Ph.D. studies.